Uncategorized Armata Pharmaceuticals announces positive phage therapy trials 1 Jun 20251 Jun 2025 Armata Pharmaceuticals Announces Positive Topline Data from the Phase 1b/2a diSArm Study of Intravenously Administered AP-SA02 in Complicated Staphylococcus aureus Bacteremia Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the…
PHAGElogist 